Africa-Press – Gambia. Haryana Medical Services Corporation Limited (HMSCL) has issued a show-cause notice to Sonepat-based Maiden Pharmaceuticals after its 19 batches of albendazole tablets, used in the treatment of parasitic worm infections, failed the quality test.
The firm is already under the scanner over its four contaminated cough syrups linked to the death of more than 66 children in Gambia.
The firm has been told to reply to the notice, dated November 1, within seven days. Following this, an order for blacklisting the firm could be issued. If barred, the order would be sent to other states too.
The HMSCL had procured albendazole tablets from the firm for government hospitals and dispensaries. Sources said of 23 batches of the tablets, 19 failed the quality test. Earlier on November 1, The Tribune reported that several batches of albendazole tablets had failed the “dissolution test parameter of IP (Indian Pharmacopoeia) 2018” while one batch also failed to comply with the “uniformity of weight” and “assay test by UV”.The sources said the report regarding the remaining batches was yet to come. For initiating a legal action, the state drug controller has taken samples of the tablets for testing at a government laboratory. The HMSCL has already blocked purchase orders from Maiden Pharmaceuticals, besides withdrawing medicines procured from it last year. Earlier, the Food and Drugs Administration (FDA), Haryana, had ordered Maiden Pharmaceuticals to stop manufacturing operations.
Test report of syrups awaited
For More News And Analysis About Gambia Follow Africa-Press
